Selective CD4+ T cell deletion after specific activation in HIV-infected individuals; protection by anti-CD28 monoclonal antibodies. NLM AIDSLINE Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Selective CD4+ T cell deletion after specific activation in HIV-infected individuals; protection by anti-CD28 monoclonal antibodies.

Clin Exp Immunol. 1996 Jul;105(1):31-8. Unique Identifier : AIDSLINE MED/96280774
Cottrez F; Capron A; Groux H; Unite INSERM U167, Institut Pasteur, Lille, France.


Abstract: AIDS is characterized by a progressive decline in the number of CD4+ T cells. This is preceded by an early selective defect in the proliferation of these cells to recall antigens [1-3], pokeweed mitogen (PWM) [4-6] and to superantigens (SAg) [4,7]. In contrast, the proliferative response to phytohaemagglutinin (PHA) remains intact [1,2,5]. We and others have shown that the proliferative defect in response to some stimuli was in fact due to the induction of cell death [4,7]. The activation-induced cell death mechanism that explains the proliferative defects observed in vitro might also account for the progressive in vivo deletion of CD4+ T cells. Indeed, studies performed on different models of primates have shown that induction of cell death in CD4+ T cells was detected only when T cells were isolated from animals infected with a type of retrovirus that induces an AIDS-like disease [8]. This correlation prompted us to analyse further the mechanism of HIV-induced activation cell death to determine the specificity and rate of induction of cell death. T cells from HIV-infected individuals were activated with superantigens and the V beta T cell receptor (TCR) expression analysed. Data presented here show that cell death is restricted to activated CD4+ T cells, and does not affect bystander cells. More importantly, addition of anti-CD28 MoAb specifically inhibited the induction of apoptosis, raising possibilities for therapy.
Keywords: Antibodies, Monoclonal/PHARMACOLOGY/*THERAPEUTIC USE Antigens, CD28/*IMMUNOLOGY Apoptosis/IMMUNOLOGY Base Sequence Cell Division/IMMUNOLOGY Child *Clonal Deletion CD4-Positive T-Lymphocytes/*IMMUNOLOGY Enterotoxins/PHARMACOLOGY Flow Cytometry Human HIV Infections/*IMMUNOLOGY/*THERAPY Immunosuppressive Agents/PHARMACOLOGY Lymphocyte Transformation/*IMMUNOLOGY Molecular Sequence Data Polymerase Chain Reaction Staphylococcus aureus/IMMUNOLOGY Superantigens/IMMUNOLOGY Support, Non-U.S. Gov't Twins, Monozygotic JOURNAL ARTICLEKWDantibodies,monoclonal/pharmacology/KWDtherapeuticuseantigens,cd28/KWDimmunologyapoptosis/immunologybasesequencecelldivision/immunologychildKWDclonaldeletioncd4-positivet-lymphocytes/KWDimmunologyenterotoxins/pharmacologyflowcytometryhumanhivinfections/KWDimmunology/KWDtherapyimmunosuppressiveagents/pharmacologylymphocytetransformation/KWDimmunologymolecularsequencedatapolymerasechainreactionstaphylococcusaureus/immunologysuperantigens/immunologysupport,non-uKWDsKWDgov'ttwins,monozygoticjournalarticle
961130
M96B1844

Copyright © 1996 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .